Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE study PUL 2.0 year-over-year decline attenuated to approximately 1 point Findings to be presented alongside previously reported HOPE-3 Phase 3 results, which met its primary and key secondary endpoints with statistical significance Deramiocel maintains a favorable safety pro both studies, with no new safety signals HOPE-2 OLE data featured in a late-breaking session; HOPE-3 in a cardiac care ses

The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said. Merck KGaA has agreed to buy Bio-Techne for $11.3 billion to acquire consumables and equipment used in activities including the production of advanced therapeutics. Bio-Techne provides products for use across drug discovery, development and manufacturing, as well as for diagnostics. The development and manufacturing of advanced therapeutics is the smallest

June 25, 2026 -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation. Pursuant to the definitive agreement, the Samsung entities invested $110 million in GRAIL through the purchase of shares of GRAIL common stock at a price of $70.05 per share, representing a long-term investment in support of GRAIL's growth

June 26, 2026 -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA stage. As a global pioneer in novel antiplatelet agents, Sumecigrel is expected to provide a new and improved treatment option to tens of millions of patients with cardiovascular and cerebrovascular diseases. Sumecigrel Capsule is

Lead oral compounds demonstrated up to 25% body weight reduction with preferential fat loss, preserved lean mass, and broad metabolic improvements in DIO models June 25, 2026 -- Mwyngil Therapeutics, a biotech company focused on developing innovative small molecule therapeutics for cardiometabolic disease, today announced positive in vivo proof-of-concept results from its GPR75 inverse agonist program, supporting the potential of GPR75 modulation as a differentiated therapeutic approach for obe

June 25, 2026 -- Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating adibelivir (IM-250) for the treatment of recurrent genital herpes. The initiation of patient dosing marks a significant value-inflection point for the company and advances its lead program into proof-of-concept development. The Phase 2a study is des

Novartis will pay biotechnology startup Antares Therapeutics $105 million as part of a multi-target research collaboration to find the Swiss pharmaceutical giant new cancer medicines. According to the terms of the dealannounced Wednesday, Antares stands to gain as much as $1.8 billion in additional payments if it discovers worthwhile targets and hits certain development and commercialization milestones. It’s also eligible for tiered royalties in “the low double-digit range” on resulting products

Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities. Revolution Medicines’ second RAS inhibitor elicited encouraging response rates in a Phase 1/2 study of pancreatic cancer, further strengthening the biotech’s leadership position in this disease. Revolution’s lead asset, daraxonrasib, made waves in April when the company announced that it doubled overall survival versus chemot

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors Proceeds will support global Phase 3 trials of IBI324 (Ollin R&D code: OLN324), a potential best-in-class VEGF/Ang2 bispecific antibody, in $15 billion retina market addressing leading causes of vision loss OLN324 demonstrated faster and greater retinal drying and numerically greater vision gains versus Vabysmo® in a randomized head-to-head proof of concept

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements — June 25, 2026 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (